|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the LLY 10-K filed Feb 22, 2010. Boehringer
Ingelheim
We are in a collaborative arrangement with Boehringer Ingelheim
(BI) to jointly market and promote Cymbalta, a product for the
treatment of major depressive disorder, diabetic peripheral
neuropathic pain, generalized anxiety disorder, and
fibromyalgia, outside the U.S. Pursuant to the terms of the
agreement, we generally share equally in development, marketing,
and selling expenses, and pay BI a commission on
53
sales in the co-promotion territories. We manufacture the
product for all territories. Reimbursements or payments for the
cost sharing of marketing, selling, and administrative expenses
are recorded in the respective expense line items in the
consolidated statements of operations. The commission paid to BI
is recognized in marketing, selling, and administrative expenses.
These excerpts taken from the LLY 10-K filed Feb 27, 2009. Boehringer
Ingelheim
We are in a collaborative arrangement with Boehringer Ingelheim
(BI) to market and promote Cymbalta, a product for the treatment
of major depressive disorder, diabetic peripheral neuropathic
pain, generalized anxiety disorder, and fibromyalgia, outside
the U.S. Pursuant to the terms of the agreement, we
generally share equally in development, marketing, and selling
expenses, and pay BI a commission on sales in the co-promotional
territories. We manufacture the product for all territories.
Collaborative reimbursements or payments for the cost sharing of
marketing, selling, and administrative expenses are recorded in
the respective expense line items in the consolidated statement
of operations. The commission paid to BI is recognized in
marketing, selling, and administrative expenses.
Boehringer Ingelheim We are in a collaborative arrangement with Boehringer Ingelheim (BI) to market and promote Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and fibromyalgia, outside the U.S. Pursuant to the terms of the agreement, we generally share equally in development, marketing, and selling expenses, and pay BI a commission on sales in the co-promotional territories. We manufacture the product for all territories. Collaborative reimbursements or payments for the cost sharing of marketing, selling, and administrative expenses are recorded in the respective expense line items in the consolidated statement of operations. The commission paid to BI is recognized in marketing, selling, and administrative expenses. | EXCERPTS ON THIS PAGE:
|
| |||||||
